Development of tumor-targeting aza-vesamicol derivatives with high affinity for sigma receptors for cancer theranostics

Author:

Mishiro Kenji1ORCID,Wang Mengfei2,Hirata Saki2,Fuchigami Takeshi2ORCID,Shiba Kazuhiro3,Kinuya Seigo4,Ogawa Kazuma12ORCID

Affiliation:

1. Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan

2. Graduate School of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan

3. Research Center for Experimental Modeling of Human Disease, Kanazawa University, Takara-machi, Kanazawa, Ishikawa 920-8640, Japan

4. Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan

Abstract

[125I]15 and [125I]17 exhibited high uptake in the tumor and low uptake in non-target tissues, indicating that [123/131I]15 and [123/131I]17 are promising compounds to be used as imaging and therapeutic probes for sigma receptor-positive tumors.

Funder

Takeda Science Foundation

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3